Respiratory Syncytial Virus (RSV) Vaccine (recombinant, adjuvanted)
AREXVY Supplier: GlaxoSmithKline Inc.

RECOMMENDED BY THE NATIONAL ADVISORY COMMITTEE ON IMMUNIZATION BUT NOT PROVIDED FREE IN BC:

Strong recommendation:

- Adults 75 years of age and older
- Adults 60 years of age and older who are residents of nursing homes and other chronic care facilities

Discretionary recommendation:

- Adults 60-74 years of age

This vaccine is not approved for use in pregnancy. This vaccine is not indicated for individuals under 60 years of age, with the exception of those 50-59 years of age who are at increased risk for RSV disease.

DOSES AND SCHEDULE:

- 1 dose given as 0.5 mL **IM**.

ADMINISTRATION:

- Product needs to be reconstituted. Use the diluent provided with the vaccine.
- Administer the entire volume of the reconstituted product.

BOOSTER DOSES:

No booster doses are recommended at this time.

SEROLOGICAL TESTING:

Serological testing is not recommended before or after immunization.

CONTRAINDICATIONS:

1. History of anaphylactic reaction to a previous dose of any RSV vaccine or to any component of AREXVY.

PRODUCT COMPONENTS:

Potential allergens: polysorbate 80.

Other components: cholesterol, dioleoyl phosphatidylcholine, dipotassium phosphate,disodium phosphate anhydrous, 3-O-desacyl-4'-monophosphoryl lipid A, potassium dihydrogen phosphate, *Quillaja saponaria* Molina fraction 21, sodium chloride, trehalose dihydrate.

PRECAUTIONS:

Not applicable.

Respiratory Syncytial Virus (RSV) Vaccine (recombinant, adjuvanted)
AREXVY Supplier: GlaxoSmithKline Inc.

SPECIAL CONSIDERATIONS:

- AREXVY can be administered concomitantly or at any time before or after the administration of other vaccines.[A]
- The duration of protection of RSV vaccines is not yet known and it is unclear if the protection offered by vaccination can be boosted by subsequent doses of vaccine. Therefore, individuals 60-74 years of age who are not at increased risk of severe disease may want to discuss deferring vaccination with their health care provider to a future time when they may be at greater risk of severe disease.
- AREXVY may be considered for individuals 50-59 years of age who are at increased risk for RSV disease.

ADVERSE EVENTS:

Local: pain, redness, swelling.

Systemic: fever, fatigue, headache, myalgia, arthralgia.

Although safety data are limited, early safety data suggest a potential increased rate of atrial fibrillation events and inflammatory neurologic events, including Guillain-Barré syndrome, after administration of RSV vaccines in adults 60 years of age and older.

[A] Some studies suggest that concurrent administration of the RSV and influenza vaccines in adults may result in a lower immune response, but the clinical significance of this is unknown.